1959 Fiat Jolly 600 "barn Find" - Matching Numbers With Only 5k Km From New on 2040-cars

Auto blog

Likely Fiat 500X replacement caught in new spy photos

Fiat is testing a new baby crossover that will likely be the replacement for the 500X crossover. The 500X never set the American market on fire despite its attractive styling and nimble handling, sadly, and suffice it to say that Fiat noticed. It's likely we won't see whatever this is come stateside, at least not in the near-term. Fiat has made it clear that its future in America is limited to the electric 500e in all of its (yet to be enumerated) forms. Those who want a baby Fiat crossover will have to settle for Jeep's more rugged interpretation of the same platform, the Renegade, which seems to sell well enough to justify its continued existence even in Europe, where they've made an even smaller one they're calling "Avenger." As you can see above, this prototype screams "500X;" The ride height and proportions are dead-on. It's expected to be sold with both ICE and EV powertrains initially, but if previous Fiat efforts are any indication (the current 500X went into production in 2007; the 500x in 2014), it could very well remain in circulation long enough to still be on the market when Europe's mandate for 100% electric new-vehicle sales kicks in in 2035. That means we're likely to see the petroleum-based models phased out over the course of its lifespan.  It might seem premature to dismiss this new model as a Europe-only venture considering that the car it is expected to replace (500X) was itself branded as an offshoot of the 500. Could we not see a 500Xe? Well, that train goes off the rails in the face of information provided by our spy photographer, who says this is likely to be sold as a revival of the long-departed Fiat 600 nameplate, rather than the 500. A rose by any other name might smell as sweet, but a model number starting with a "6" appears to be where Fiat has chosen to draw the line, at least for now.  Related video: This content is hosted by a third party. To view it, please update your privacy preferences. Manage Settings.

Fiat sells part of its historic Lingotto factory in Turin

Stellantis-owned Fiat is selling part of its historic Lingotto factory in Turin, Italy, in a bid to downsize its real estate assets. Inaugurated in 1923, the facility built numerous Fiat models until it closed in 1982, and a test track built on its roof made it famous all around the world. Italian website Motori Online reported that digital services specialist Reply purchased a roughly 215,000-square-foot chunk of the complex with plans to turn it into an office building. There's no word yet on how much Fiat sold the space for, but most sources agree that the firm will retain ownership of the test track. And, the building itself isn't going anywhere: Reply will move in, but it won't knock it down and rebuild it. The test track that made Lingotto famous wasn't merely a gimmick: it was an important part of the production process for several decades. Raw materials entered the building on the ground floor and cars made their way through several stations scattered across the five floors before ending up (in one piece) on the roof. They were then driven for about half a mile before being sent out of the complex. This sped up the production process because road testers could put new cars through their paces without having to leave Turin, and it allowed Fiat to test prototypes without worrying about getting spotted by spy photographers. The track was also featured in the 1969 movie The Italian Job.  This content is hosted by a third party. To view it, please update your privacy preferences. Manage Settings. Fiat isn't the first Stellantis brand to leave its historic home. Peugeot left its headquarters in downtown Paris for the same reasons in 2017. Related video: This content is hosted by a third party. To view it, please update your privacy preferences. Manage Settings. Auto News Plants/Manufacturing Fiat

Fiat Chrysler says it did not know about Marchionne's illness

ZURICH/MILAN — Fiat Chrysler said it knew nothing about the medical condition of Sergio Marchionne after a Swiss hospital said on Thursday it had been treating the deceased chief executive for more than a year. "Due to medical privacy, the company had no knowledge of the facts relating to Mr. Marchionne's health," a Fiat Chrysler spokesman said. Questions have been raised about how long Marchionne, who died on Wednesday, was ill and how much the company knew before it made the situation public. Marchionne rescued Fiat and Chrysler from bankruptcy after taking the wheel of the Italian carmaker in 2004 and he multiplied Fiat's value 11 times through 14 years of canny dealmaking. He was due to step down at FCA in April next year. "The company was made aware that Mr. Marchionne had undergone shoulder surgery and released a statement about this," the spokesperson said. "On Friday, July 20, the company was made aware with no detail by Mr. Marchionne's family of the serious deterioration in Mr. Marchionne's condition and that as a result he would be unable to return to work. The company promptly took and announced the appropriate action the following day." Asked whether the scope of the statement included the board and the chairman, the company declined to comment. In emailed comments, Marchionne's family confirmed the companies had not been aware of his health conditions. "At the end of last week FCA was made aware Sergio Marchionne would no longer be able to return to work without mentioning any further details," the family said. The announcement of the death of Marchionne, 66, one of the auto industry's most tenacious and respected CEOs, drew tributes from rivals and tears from his closest colleagues on Wednesday. University Hospital Zurich said earlier on Thursday Marchionne had been treated for a serious illness for more than a year before his death. Marchionne had fallen gravely ill after what the company had described as shoulder surgery at a Zurich hospital. He was replaced as chief executive last weekend after Fiat Chrysler (FCA) said his condition had worsened. "Mr. Sergio Marchionne was a patient at USZ. Due to serious illness, he had been the recipient of recurring treatment for more than a year," the hospital said in a statement. "Although all the options offered by cutting-edge medicine were utilized, Mr.